Patents by Inventor Siegfried Matzku
Siegfried Matzku has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20060153770Abstract: A method of treating tumors, such as prostate tumors, breast tumors, non-Hodgkin's lymphoma, and the like, includes the sequential steps of administering to the patient at least one dose of an antiangiogenic cyclo-arginine-glycine-aspartic acid-containing pentapeptide (cRGD pentapeptide); administering to the patient an anti-tumor effective amount of a radioimmunotherapeutic agent (RIT); and then administering to the patient at least one additional dose of cRGD pentapeptide. The cRGD pentapeptide is preferably cyclo-(Arg-Gly-Asp-D-Phe-[N-Me]-Val), and the RIT is preferably a radionuclide-labeled chelating agent-ligand complex in which chelating agent is chemically bonded to a tumor-targeting molecule, such as a monoclonal antibody.Type: ApplicationFiled: March 17, 2006Publication date: July 13, 2006Inventors: Sally DeNardo, Patricia Burke, Gerald DeNardo, Simon Goodman, Siegfried Matzku, Kerstin Matzku
-
Patent number: 7029652Abstract: A method of treating tumors, such as prostate tumors, breast tumors, non-Hodgkin's lymphoma, and the like, includes the sequential steps of administering to the patient at least one dose of an antiangiogenic cyclo-arginine-glycine-aspartic acid-containing pentapeptide (cRGD pentapeptide); administering to the patient an anti-tumor effective amount of a radioimmunotherapeutic agent (RIT); and then administering to the patient at least one additional dose of cRGD pentapeptide. The cRGD pentapeptide is preferably cyclo-(Arg-Gly-Asp-D-Phe-[N-Me]-Val), and the RIT is preferably a radionuclide-labeled chelating agent-ligand complex in which chelating agent is chemically bonded to a tumor-targeting molecule, such as a monoclonal antibody.Type: GrantFiled: July 31, 2002Date of Patent: April 18, 2006Assignees: The Regents of the University of California, Merck Patent GmbHInventors: Sally J. DeNardo, Patricia A. Burke, Gerald L. DeNardo, Simon Goodman, Kerstin Matzku, legal representative, Siegfried Matzku, deceased
-
Patent number: 7011967Abstract: Seripancrin polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Seripancrin polypeptides and polynucleotides in diagnostic assays.Type: GrantFiled: July 4, 2000Date of Patent: March 14, 2006Assignee: Merck Patent GmbHInventors: Britta Sundermann, Uwe Hofmann, Siegfried Matzku, Oliver Wilbert
-
Patent number: 6979726Abstract: The present invention relates to new fusion proteins which consist of a tumor-associated targeting element preferentially a monoclonal antibody or a fragment thereof recognizing a molecule which is preferentially expressed on human tumor cells such as the human epidermal growth factor receptor (EGFR), and a biologically active ligand such as a growth and/or differentiation factor. The resulting fusion protein may be used to deliver the biologically active ligand to a specific target cell or tissue. The new immunoconjugates can be used in tumor therapy.Type: GrantFiled: December 23, 1994Date of Patent: December 27, 2005Assignee: Merck Patent GmbHInventors: Ilka von Hoegen, Uwe Hofmann, Carlota-Silvia Jaggle, Wolfgang Strittmatter, Jörg Stadlmüller, Siegfried Matzku
-
Publication number: 20030143157Abstract: A method of treating tumors, such as prostate tumors, breast tumors, non-Hodgkin's lymphoma, and the like, includes the sequential steps of administering to the patient at least one dose of an antiangiogenic cyclo-arginine-glycine-aspartic acid-containing pentapeptide (cRGD pentapeptide); administering to the patient an anti-tumor effective amount of a radioimmunotherapeutic agent (RIT); and then administering to the patient at least one additional dose of cRGD pentapeptide. The cRGD pentapeptide is preferably cyclo-(Arg-Gly-Asp-D-Phe-[N-Me]-Val), and the RIT is preferably a radionuclide-labeled chelating agent-ligand complex in which chelating agent is chemically bonded to a tumor-targeting molecule, such as a monoclonal antibody.Type: ApplicationFiled: July 31, 2002Publication date: July 31, 2003Inventors: Sally J. DeNardo, Patricia A. Burke, Gerald L. DeNardo, Simon Goodman, Siegfried Matzku
-
Patent number: 6410270Abstract: The invention relates to a fed-batch fermentation process which uses special E. coli host/vector systems for the purpose of efficiently forming recombinant proteins, in particular recombinant antibody molecules, preferably antibody fragments such as miniantibodies. Under the given conditions, the E. coli cells are able to grow at a maximum specific growth rate up to very high cell densities. After the recombinant product formation has been switched on, it is only the formed product which restricts growth; there is no growth restriction due to substrates or metabolic by-products. High space-time yields of recombinant proteins can be achieved in this manner.Type: GrantFiled: November 16, 1998Date of Patent: June 25, 2002Assignee: Merck Patent GesellschaftInventors: Wolfgang Strittmatter, Siegfried Matzku, Dieter Riesenberg, Uwe Horn, Uwe Knüpeer, Marian Kujau, Rolf Wenderoth, Andreas Plückthun, Anke Krebber
-
Patent number: 5885575Abstract: The inventon relates to antibodies that react with a variant epilope in the extracellular region of a variant CD44 polypeptide, wherein the variant epitope has the amino acid sequence:I S S T I S T T P R A P D H T K Q N Q D W T Q W N P S H S N P EV L L Q T T T R M T D V D R N G T T A Y E G N W N P E A H P P LI H H E H H E E E E T P H S T S T I O A T P S S T T E E T A T QK E Q W F G N R W H E G Y R Q T P R E D S H S T T G T A A A S AH T S H P M Q G R T T P S P E D S S W T D F F N P I S H P M G RG H Q A G R R (residues 53-219 of SEQ ID NO:4). Methods of using the antibodies to identify variant epitopes also are provided.Type: GrantFiled: June 7, 1995Date of Patent: March 23, 1999Assignees: Kernforschungszentrum Karlsruhe GmbH, Universitaet Karlsruhe, Deutsches KrebsforschungszentrumInventors: Peter Herrlich, Helmut Ponta, Ursula Guenthert, Siegfried Matzku, Achim Wenzel
-
Patent number: 5824782Abstract: The invention provides new immunoconjugates comprising a mono-clonal antibody or a fragment thereof specific for the human EGF-receptor molecule and a member of the chemokine family, preferably selected from the C-X-C family, e.g. lnterleukin-8 (IL-8). The immunoconjugates induce cytotoxic and chemotactic activity and are suitable for a targeted tumor therapy.Type: GrantFiled: September 15, 1995Date of Patent: October 20, 1998Assignee: Merck Patent Gesellschaft mit beschrankter HaftungInventors: Wolfgang Holzer, Ilka von Hoegen, Wolfgang Strittmatter, Siegfried Matzku
-
Patent number: 5760178Abstract: A monoclonal antibody (MAb1.1ASML) directed against a surface glycoprotein of the metastasizing rat pancreatic carcinoma cell line BSp73ASML, was used to identify and isolate a complementary DNA (cDNA) clone capable of encoding for a glycoprotein with partial homology to CD44, a presumed adhesion molecule. This clone, which was subsequently designated pMeta-1, contains an additional extracellular domain of 162 amino acids inserted into the CD44 protein between amino acid positions 223 and 247 (by analogy to human and murine CD44). This new variant was expressed only in the metastasizing cell lines of two rat tumors, the pancreatic carcinoma BSp73 and the mammary adenocarcinoma 13762NF; it was not expressed in non-metastasizing tumor cell lines nor in normal rat tissues. Overexpression of pMeta-1 in the nonmetastasizing BSp73AS cell line suffices to establish full metastatic behavior. The variant-specific rat CD44 sequence was used to isolate a cDNA clone encoding for a human homologue as well.Type: GrantFiled: June 7, 1995Date of Patent: June 2, 1998Assignees: Kernforschungszentrum Karlsruhe GmbH, Universitaet Karlsruhe, KrebsforschungszentrumInventors: Peter Herrlich, Helmut Ponta, Ursula Guenthert, Siegfried Matzku, Achim Wenzel
-
Patent number: 5506119Abstract: The presence of certain extracellular regions ("ECR") from human and rat variants of the CD44 membrane glycoprotein have been found to be associated with metastasis ability in tumor cells. Isolated polynucleotides encoding the ECRs permit expression of the ECR polypeptide, which in turn can be used as an antigen to obtain monoclonal antibodies that recognize the ECR polypeptide. The anti-ECR monoclonal antibodies have the ability to prevent metastasis by tumor cells that would otherwise metastasize and spread.Type: GrantFiled: November 9, 1992Date of Patent: April 9, 1996Assignees: Kernforschungszentrum Karlsruhe GmbH, Universitaet Karlsruhe, Deutsches KrebsforschungszentrumInventors: Peter Herrlich, Helmut Ponta, Ursula Guenthert, Siegfried Matzku, Achim Wenzel